Open Nav

Tuesday, April 8, 2014, 9:30 - 10:25am
Coriander Room, 2nd floor

The surge of biotech IPOs has not been limited to the U.S., as Asian investors in both Japan and Taiwan have warmly greeted a new generation of biotechs. Four biotech CEOs, who collectively have raised more than $260 million in IPOs, will discuss how they navigated the road to the public markets, how the investor climate has changed, how the next-generation Asian biotechs are different than the first generation, and how they plan to create value for their shareholders and patients, including their strategies for partnering and globalizing.